Fortis Healthcare Completes Debenture Amendment Process

Fortis Healthcare has successfully received final regulatory approval for modifications to its non-convertible debentures (NCDs). The company announced on December 19, 2025, that BSE Limited has granted approval for the alterations in debenture terms, marking the completion of a regulatory process that began earlier this month.

Regulatory Approval Details

The key timeline and approval information includes:

Compliance and Disclosure

The approval was disclosed under Regulation 30 and 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Company Secretary and Compliance Officer Satyendra Chauhan formally communicated the development to both NSE and BSE, ensuring full regulatory compliance.

Strategic Financial Management

This approval represents the culmination of Fortis Healthcare's efforts to optimize its debt structure. The modifications to NCD terms are part of the company's broader financial management strategy, aimed at enhancing operational flexibility and improving its overall debt profile.

Market Implications

With regulatory approval now secured, the modified debenture terms will take effect, potentially impacting the company's financial obligations and cash flow management. The successful completion of this regulatory process demonstrates Fortis Healthcare's commitment to maintaining transparent corporate governance practices while actively managing its financial instruments.

The healthcare major's proactive approach to debt restructuring reflects its focus on maintaining a robust financial foundation to support its operations in the competitive healthcare sector.

Fortis Healthcare Limited , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, with significant growth in both revenue and profitability.

Strong Revenue Growth

The company's consolidated revenue for Q2 FY26 stood at INR2,331.00 crores, marking a 17.3% increase compared to the same period last year. This growth was primarily driven by the hospital segment, which saw a 19.3% year-on-year increase in revenue to INR1,974.00 crores. The diagnostic business also contributed positively, with a 7.1% growth in net revenue to INR357.00 crores.

Improved Profitability

Fortis Healthcare's consolidated operating EBITDA surged by 28% to INR556.00 crores, with the EBITDA margin expanding to 23.9% from 21.9% in Q2 FY25. The hospital business reported an operating EBITDA of INR452.00 crores, showing a 150 basis points improvement in margin to 22.9%. The company's profit after tax before exceptional items increased by 20.7% to INR305.00 crores.

Key Operational Metrics

Expansion and Strategic Initiatives

Fortis Healthcare has been actively pursuing growth opportunities:

• Entered a 15-year lease agreement for a 200-bed multi-specialty hospital in Greater Noida.
• Signed an O&M agreement for a 550-bed greenfield super specialty hospital in Lucknow.
• Acquired Shrimann Super Speciality Hospital in Jalandhar, adding 190 operational beds.
• Entered into an O&M agreement with Gleneagles India to manage five hospitals and a clinic.
• Added 550 operational beds in H1 FY26 through various initiatives.

Diagnostic Business Performance

The diagnostic arm, Agilus Diagnostics, reported a 7.3% increase in gross revenue to INR400.00 crores. The operating EBITDA margin for this segment improved to 26.1% from 21.5% in Q2 FY25.

Dr. Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, commented on the results: "We continue to witness a healthy growth momentum in Q2 FY26 and H1 of FY26. Both our business segments, Hospitals and Diagnostics, continue to perform well both in terms of revenue and margins."

With these positive results and ongoing expansion initiatives, Fortis Healthcare continues to strengthen its position in the Indian healthcare sector, focusing on both organic growth and strategic acquisitions to enhance its service offerings and market presence.